Rolling coverage of the latest economic and financial news
- UK exports and imports with Germany fell last year
- Brexit damaging trade with EU, says public accounts committee
- National insurance rise could mean 1m destitute households in UK, says thinktank
- EU hopes €43bn plan will fix chip shortages as supply chain crisis bites
GlaxoSmithKline made £1.4bn from Covid-related sales last year, mostly from its antibody drug Xevudy, as it unveiled better-than-expected results ahead of what its boss Dame Emma Walmsley describes as a “landmark year”.
Ahead of the spin-off and stock market flotation of its consumer arm this summer, GSK reported total sales of £34bn for 2021, similar to the previous year. The consumer healthcare business contributed £9.6bn, down 4% from 2020. GSK’s annual profit before tax fell to £5.1bn, from £6.4bn in 2020.
“This is going to be a landmark year for GSK, with a step-change in growth expected and multiple research & development catalysts, including milestones on up to seven key late-stage pipeline assets.
2022 is also the year when we demerge our world-leading consumer healthcare business.”
